Molecular Diagnostics in Cytology and Small Biopsy Specimens of Non-Small Cell Lung Cancer


Non-small cell lung cancer is among the most common cancer types in males and females, in the US and worldwide, and currently has the highest mortality among all cancer types. Guidelines are continuously updated to reflect the most current state of knowledge on biomarker testing in this setting, and updated recommendations are in place as to what testing needs to be performed, based on pathological diagnosis and clinical presentation, along with what specimens can be tested and what characteristics the testing platforms utilized need to have. As the number of possibly actionable tests to be performed is increasing, it is important for the clinician and the pathologist to have an understanding of the clinical and technical aspect of this testing, in order to optimize the way specimens are procured and utilized for testing, especially in the setting of cytology and small biopsy specimens that are very common in lung cancer.

Originally presented on February 12, 2020 in Park City, Utah.

Lecture Presenter

Georgios Deftereos, MD

Georgios Deftereos, MD

Assistant Professor of Pathology (Clinical)
University of Utah School of Medicine
Section Head and Medical Director, Molecular Oncology
ARUP Laboratories

Dr. Deftereos is an assistant professor of pathology at the University of Utah School of Medicine. He received his MD from the University of Bari Aldo Moro in Italy. Prior to his pathology training, Dr. Deftereos completed a research fellowship focusing on HPV and gynecological malignancies at the University of Washington. He then completed a residency in anatomic and clinical pathology at Pittsburgh's Allegheny General Hospital, followed by consecutive clinical fellowships in cytopathology and molecular genetic pathology at the University of Washington. Dr. Deftereos is board certified in anatomic pathology, clinical pathology, cytopathology, and molecular genetic pathology, and provides service in the areas of molecular oncology and cytopathology. His research interests include epigenetics of solid tumors and minimally invasive precision diagnostics, with emphasis on the use of molecular testing in cytopathology of solid tumors.


After this presentation, participants will be able to:

  • Apply current recommendations for testing in non-small cell lung carcinomas.
  • Discuss testing of small biopsies and cytology specimens of non-small cell lung carcinomas.
  • Discuss how specimens are triaged for different types of biomarker testing in non-small cell lung cancer.

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories